Search clinical trials for: Docetaxel plus carboplatin

Total 17717 results

Beijing Tongren Hospital

Recruiting

Evaluating the Efficacy and Safety of Pembrolizumab Plus Standard Chemotherapy in the Neoadjuvant Treatment of Local Advanced (LA) HNSCC

Head and Neck Squamous Cell Carcinoma | Neoadjuvant Therapy | Pembrolizumab

China
Biocon Biologics UK Ltd

Not yet recruiting

Efficacy and Safety of the Proposed Biosimilar Pertuzumab (PERT-IJS) Versus EU-Perjeta® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer

HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients
AstraZeneca

Recruiting

A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients (TRITON)

Carcinoma, Non-Small-Cell Lung

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Recruiting

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Early Stage Triple-Negative Breast Carcinoma

United States, Puerto Rico
Hirva Mamdani
AstraZeneca; Barbara Ann Karmanos Cancer Institute

Recruiting

MOnaliZumab in Combination With durvAlumab (MEDI4736) Plus Platinum-based chemotheRapy for First-line Treatment of Extensive Stage Small Cell Lung Cancer (MOZART)

Small Cell Lung Cancer | SCLC | Extensive Stage Small Cell Lung Cancer

United States
Karolinska University Hospital

Recruiting

Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer (ARIADNE)

Breast Cancer

Sweden
Shengjing Hospital

Recruiting

Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast Cancer

Breast Cancer

China
Shengjing Hospital

Recruiting

A Study of Immunotherapy Combined With Neoadjuvant Therapy Versus Neoadjuvant Therapy for Breast Cancer

Stage II-III Breast Cancer

China
Georgetown University

Recruiting

RAGE Inhibition to Decrease Cardiotoxicity in Women With Early Breast Cancer (RAGE)

Non-metastatic Breast Cancer | Cancer Related Cognitive Decline

United States
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
CSPC Ouyi Pharmaceutical Co., Ltd.

Recruiting

Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast Cancer

Breast Cancer

China
National Cancer Institute (NCI)

Recruiting

Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers

Recurrent Head and Neck Squamous Cell Carcinoma | Recurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Metastatic Head and Neck Squamous Cell Carcinoma | Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Stage IV Hypopharyngeal... and other conditions

United States
Ruijin Hospital

Not yet recruiting

Tislelizumab Plus TP as Neoadjuvant Therapy for Local Advanced Cervical Carcinoma (TiTanec)

Cervical Squamous Cell Carcinoma

China
Shanghai Pulmonary Hospital, Shanghai, China

Not yet recruiting

Adjuvant Toripalimab Plus Chemotherapy for EGFR/ALK Mutation Negative Stage II-IIIB(N2) NSCLC (LungMate-008)

Non Small Cell Lung Cancer
Karolinska Institutet
The Swedish Research Council; AstraZeneca; Janssen Pharmaceutica N.V., Belgium; Kom Op Tegen Kanker and other collaborators

Recruiting

ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer (ProBio)

Metastatic Castration-resistant Prostate Cancer (mCRPC) | Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Sweden, Belgium, Switzerland, Norway
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Recruiting

Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery

Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7 | Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v6 and v7

United States
Shanghai Jiao Tong University School of Medicine
Shanghai 10th People's Hospital; Jiangxi Provincial Cancer Hospital; Shanghai... and other collaborators

Recruiting

A Randomised Trial of Chemotherapy Plus Surgery for Recurrent Non-Small Cell Lung Cancer (CCODG-NSCLC)

Recurrent Non-small Cell Lung Cancer

China
Dr. Gordon Buduhan
University of Toronto; London Health Sciences Centre; CancerCare Manitoba

Recruiting

Preoperative Chemotherapy vs. Chemoradiation in Esophageal / GEJ Adenocarcinoma (POWERRANGER)

Esophageal Cancer | Adenocarcinoma, Esophageal | Adenocarcinoma, Gastroesophageal Junction

Canada
National Cancer Institute (NCI)

Active, not recruiting

Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Recurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7 | Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7 | Stage IVA Oropharyngeal Squamous... and other conditions

United States, Puerto Rico, South Africa
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer

Stage IB Breast Cancer AJCC v7 | Stage IIA Breast Cancer AJCC v6 and v7 | Stage IIB Breast Cancer AJCC v6 and v7 | Stage IIIA Breast Cancer AJCC v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7 | HER2-Positive Breast Carcinoma | Hormone Receptor-Positive Breast Carcinoma

United States, Puerto Rico
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Docetaxel, Cisplatin and Fluorouracil in Treating Patients With Previously Untreated Stage II-IV Nasal Cavity and Paranasal Sinus Cancer

Sinonasal Undifferentiated Carcinoma | Locally Advanced Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma | Nasal Cavity and Paranasal Sinus Poorly Differentiated Carcinoma | Stage II Nasal Cavity and Paranasal Sinus Cancer AJCC v8 | Stage III Nasal Cavity and Paranasal Sinus Cancer... and other conditions

United States
Caigang Liu
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients

HER2-positive Breast Cancer

China
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Clear Cell Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Mucinous... and other conditions

United States, Korea, Republic of, Japan
University of Kansas Medical Center
Merck Sharp & Dohme LLC

Active, not recruiting

Neoadjuvant Phase II Study of Pembrolizumab And Carboplatin Plus Docetaxel in Triple Negative Breast Cancer (NeoPACT)

Triple-negative Breast Cancer

United States
Bristol-Myers Squibb

Active, not recruiting

A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

Russian Federation, Belgium, United States, Australia, Argentina, Brazil, Canada, China, Czechia, France, Germany, Ireland, Italy, Japan, Mexico, Netherlands, Poland, Puerto Rico, Romania, Spain, Taiwan, United Kingdom
GlaxoSmithKline
Merck Sharp & Dohme LLC

Completed

Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)

Neoplasms

United States, Australia, Spain, Italy, Japan, Netherlands, Canada, France, China
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Cisplatin, Docetaxel, and Pembrolizumab in Treating Patients With Stage II-III Laryngeal Cancer

Stage III Laryngeal Cancer AJCC v8 | Laryngeal Squamous Cell Carcinoma | Stage II Laryngeal Cancer AJCC v8

United States
M.D. Anderson Cancer Center

Active, not recruiting

Nivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer

Stage IB Lung Non-Small Cell Carcinoma AJCC v7 | Stage II Lung Non-Small Cell Cancer AJCC v7 | Stage IIA Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIB Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIIA Lung Non-Small Cell Cancer AJCC v7 | Stage I Lung Non-Small Cell Cancer AJCC v7 | Stage...

United States
Shanghai Institute Of Biological Products
Fudan University

Completed

A Study Of SIBP-01 Or CN-Trastuzumab Plus Docetaxel And Carboplatin In HER2 Positive Breast Cancer

HER2-positive Early Breast Cancer

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Combination Chemotherapy With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck

Metastatic Squamous Cell Carcinoma of the Hypopharynx | Metastatic Squamous Cell Carcinoma of the Larynx | Metastatic Squamous Cell Carcinoma of the Oral Cavity | Metastatic Squamous Cell Carcinoma of the Oropharynx | Recurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous... and other conditions

United States
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Active, not recruiting

A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC) (CheckMate 816)

Non Small Cell Lung Cancer

United States, China, Hungary, Brazil, Argentina, Canada, France, Greece, Italy, Japan, Korea, Republic of, Romania, Spain, Taiwan, Turkey
Peking Union Medical College Hospital

Completed

Neoadjuvant Pembrolizumab Plus Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Nabil Adra
Genentech, Inc.; Indiana University School of Medicine

Terminated

Trial of Atezolizumab Plus Chemotherapy After Progression on PD-1 or PD-L1 in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma

Urothelial Carcinoma

United States
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

Phase III Study of Toripalimab Versus Placebo Plus Chemotherapy in Resectable NSCLC

Stage II-III Non-small Cell Lung Cancer

China
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Docetaxel Plus Carboplatin in Treating Patients With Advanced Cancer of the Esophagus

Esophageal Cancer

United States, Puerto Rico, South Africa
Jonsson Comprehensive Cancer Center
Merck Sharp & Dohme LLC

Completed

Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate

Urothelial Carcinoma | Castration-Resistant Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Metastatic Bladder Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Stage III Bladder Cancer AJCC v8 | Stage III Urethral Cancer AJCC v8 | Stage IV Bladder Cancer AJCC v8 | Stage IV Urethral... and other conditions

United States
Henan Cancer Hospital

Completed

Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Docetaxel and Carboplatin in HER2 Positive Breast Cancer Patients.

HER2 Positive Breast Cancer

China
Novartis Pharmaceuticals

Terminated

An Open-label, Dose Escalation Multi-center Study in Patients With Advanced Cancer to Determine the Infusion Rate Effect of ASA 404 With Paclitaxel Plus Carboplatin Regimen or Docetaxel on the Pharmacokietics of Free and Total ASA404

Metastatic Cancer With Impaired Renal Function | Metastatic Cancer With Normal Renal Function

Belgium
NSABP Foundation Inc
Hoffmann-La Roche; Genentech, Inc.; Cancer International Research Group (CIRG)

Terminated

BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab (BETH)

Breast Cancer

Korea, Republic of, United States, Canada, Spain, Ireland, Australia, Argentina, China, United Kingdom, Germany, Brazil, Hong Kong, France, Israel, Taiwan, Serbia, Belgium, Thailand, Croatia, Egypt, Italy, Philippines, Bosnia and Herzegovina and more
M.D. Anderson Cancer Center

Completed

Carboplatin Plus Docetaxel (Taxotere) in Anaplastic Prostate Cancer

Prostate Cancer

United States
Guangdong Provincial People's Hospital

Completed

TCH Versus EC-TH as Neoadjuvant Treatment for HER2-Positive Breast Cancer (neoCARH)

HER2-Positive Breast Cancer

China
Millennium Pharmaceuticals, Inc.

Completed

Dose Escalation, Multi-arm Study of MLN4924 Plus Docetaxel, Gemcitabine, or Combination of Carboplatin and Paclitaxel in Participants With Solid Tumors

Solid Tumors

United States
Fudan University

Completed

Study Comparing Paclitaxel Plus Carboplatin Versus Anthracyclines Followed by Docetaxel as Adjuvant Chemotherapy for Triple Negative Breast Cancer (PATTERN)

Breast Cancer
Hoffmann-La Roche

Completed

A Study Evaluating Trastuzumab Emtansine Plus Pertuzumab Compared With Chemotherapy Plus Trastuzumab and Pertuzumab for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer

Breast Neoplasms

Canada, United States, France, Korea, Republic of, Spain, Belgium, Germany, Russian Federation, Taiwan, Ukraine
Shandong University

Unknown

Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Chemotherapy in Patients With HER2 Positive Breast Cancer

HER2-positive Breast Cancer
Tongji Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Docetaxel Combined With Carboplatin Plus Anlotinib as First Line Treatment in NSCLC (ALTER-L013)

NSCLC

China
Pfizer

Completed

A Study Of PF-05280014 Or Trastuzumab Plus Taxotere® And Carboplatin In HER2 Positive Breast Cancer In The Neoadjuvant Setting (REFLECTIONS B327-04)

Early Breast Cancer

Czechia, Serbia, Slovakia, United States, Belarus, Hungary, Ukraine, Italy, Poland, Russian Federation
PrECOG, LLC.
AstraZeneca

Completed

Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer

Lung Cancer | Non Small Cell Lung Cancer

United States
Finnish Lung Cancer Group
Roche Pharma AG

Completed

Erlotinib Treatment Beyond Progression in EGFR Mutant NSCLC

Non-small Cell Lung Cancer

Finland
Hoffmann-La Roche

Terminated

A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid Tumors

Neoplasms

United States
Washington University School of Medicine
Sanofi

Terminated

Carboplatin Plus Docetaxel With Day 2 Pegylated G-CSF (Neulasta®) in Patients With Advanced Stage Ovarian Carcinoma

Ovarian Cancer

United States

Search clinical trials for: Docetaxel plus carboplatin

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Georgia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations